JDRF Supports a Provincial Plan to Fund Insulin Pumps for Nova Scotians Living with Type 1 Diabetes
TORONTO (February 6, 2013) – JDRF supports a provincial plan to fund insulin pumps for individuals residing in Nova Scotia living with type 1 diabetes (T1D).
T1D is an autoimmune disease in which a person’s pancreas stops producing insulin, a hormone that enables people to get energy from food. Its onset has nothing to do with diet or lifestyle.
Affecting over 300,000 Canadians, T1D can occur at any age, leaving children and adults dependent on injected or pumped insulin for life. The number of people living with T1D is increasing by three to five percent annually - the greatest rise being in children aged five to nine years.
Insulin pump technology provides precise insulin delivery continuously day and night, helping individuals maintain glucose levels between meals, during exercise and overnight. Studies have shown that people living with T1D who use insulin pump therapy experience fewer complications and live longer, healthier lives. In fact, a better managed blood glucose regimen has been proven to reduce the number of heart, kidney and eye-related diabetes complications. By investing in insulin pump therapy in the short-term, we can take steps to lessen or prevent complications from developing later in life, which can result in savings for health care systems in the long-term.
“JDRF Nova Scotia has been actively working on securing Insulin Pump Coverage for all Nova Scotians for the past six years. It has been our longstanding goal to bring Nova Scotia’s diabetes support system inline with coverage offered by most other provinces and territories in Canada, ensuring that individuals living with T1D in Nova Scotia have every opportunity to minimize the long-term complications of this
chronic disease,” says Marilyn Holm, Regional Manager, Atlantic Canada.
JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF is now the largest charitable supporter of T1D research. The goal of JDRF research is to improve the lives of all people affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing T1D. JDRF collaborates with a wide spectrum of partners who share this goal.
Since its founding in 1970 (1974 in Canada), JDRF has awarded more than $1.7 billion (U.S.) to diabetes research. Past JDRF efforts have helped to significantly advance the care of people with this disease, and have expanded the critical scientific understanding of T1D. JDRF will not rest until T1D is fully conquered. For more information, please visit jdrf.ca.
For More Information:
Regional Manager, Atlantic Canada